Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MP 0317

Next Previous
Drug Profile

MP 0317

Alternative Names: FAP x CD40 - Molecular Partners; MP-0317

Latest Information Update: 30 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Immunotherapies; Protein-drug conjugates; Proteins
  • Mechanism of Action CD40 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Jun 2025 Molecular Partners AG in collaboration with Centre Hospitalier Universitaire de Besancon plans a phase II TACTIC trial for Cholangiocarcinoma (Late stage disease, First line therapy, Combination therapy, Inoperable/Unresectable, Metastatic disease) in France (IV) (NCT07036380)
  • 20 Jan 2025 MP 0317 is still in phase-I trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in France, Netherlands (IV) (Molecular Partners pipeline, January 2025)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in France (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top